Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Profit After Tax (2020 - 2025)

Insight Molecular Diagnostics' Profit After Tax history spans 6 years, with the latest figure at -$10.9 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 19.56% year-over-year to -$10.9 million; the TTM value through Sep 2025 reached -$60.8 million, down 31.93%, while the annual FY2024 figure was -$60.7 million, 118.36% down from the prior year.
  • Profit After Tax for Q3 2025 was -$10.9 million at Insight Molecular Diagnostics, down from -$9.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $6.0 million in Q1 2023 and bottomed at -$45.0 million in Q4 2022.
  • The 5-year median for Profit After Tax is -$9.3 million (2022), against an average of -$12.9 million.
  • The largest annual shift saw Profit After Tax crashed 468.79% in 2021 before it surged 274.6% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$35.9 million in 2021, then decreased by 25.34% to -$45.0 million in 2022, then soared by 57.94% to -$18.9 million in 2023, then plummeted by 77.14% to -$33.5 million in 2024, then surged by 67.61% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Profit After Tax are -$10.9 million (Q3 2025), -$9.7 million (Q2 2025), and -$6.7 million (Q1 2025).